SCHEMBL165211

SCHEMBL165211

COC(=O)C1CCC(c2ncc(-c3ccc(NC(=O)Nc4c(F)cccc4C(F)(F)F)cc3)s2)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.44
TEK Q02763 1/20 0.44
DGAT1 O75907 8/20 0.44
BTK Q06187 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
BRAF P15056 2/20 0.37
CSF1R P07333 2/20 0.36
RET P07949 1/20 0.36
FGFR1 P11362 1/20 0.36
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
FLT3 P36888 1/20 0.36
FRK P42685 1/20 0.36
CAMK2B Q13554 1/20 0.36
CAMK2D Q13557 1/20 0.36
NTRK3 Q16288 1/20 0.36
HIPK4 Q8NE63 1/20 0.36
AURKB Q96GD4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL158961 0.92 L3MBTL1 (0.46) KDRDGAT1BTKL3MBTL1BRAF
SCHEMBL174112 0.92 DGAT1 (0.48) KDRTEKDGAT1BTKFLT3
SCHEMBL160059 0.91 DGAT1 (0.53) KDRTEKDGAT1BTKBRAF
SCHEMBL158660 0.88 DGAT1 (0.49) KDRDGAT1BRAFCSF1RFGFR1
SCHEMBL162638 0.85 DGAT1 (0.59) KDRTEKDGAT1
SCHEMBL161939 0.84 DGAT1 (0.56) KDRDGAT1FLT3
SCHEMBL15022189 0.84 DGAT1 (0.54) KDRTEKDGAT1BRAFCSF1R
SCHEMBL163741 0.83 DGAT1 (0.48) KDRTEKDGAT1FGFR1FLT1
SCHEMBL174099 0.83 DGAT1 (0.53) DGAT1BTKL3MBTL1CSF1R
SCHEMBL160673 0.83 DGAT1 (0.49) KDRTEKDGAT1L3MBTL1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 KDR 4203/4885TEK 3387/4885DGAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.